Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
about
Why bortezomib cannot go with 'green'?Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaBlocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cellsPhase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation.Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myelomaThe ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.Discovering discovery patterns with Predication-based Semantic Indexing.The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsUse of class I histone deacetylase inhibitor romidepsin in combination regimensBortezomib and EGCG: no green tea for you?Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Targeted therapy in chronic lymphocytic leukemia: past, present, and future.The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models.CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.Molecular mechanisms of action of quercetin in cancer: recent advances.Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo.Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycleGlutathione is key to the synergistic enhancement of doxorubicin and etoposide by polyphenols in leukaemia cell lines.The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.Antidepressant-like effects of quercetin in diabetic rats are independent of hypothalamic-pituitary-adrenal axis.Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.
P2860
Q24630709-A667F807-5F88-4729-AC21-64C12F235794Q26781895-2D28DA53-0366-41CD-B927-BB84A70BE903Q28481321-F4360024-540F-4A68-B8E8-45F9B54B4D15Q33420278-FDDC72A5-7376-459D-ABB7-BFA9E7585C83Q35125652-8DA69911-C0E8-44CA-9B06-3FD906B0C15FQ35143496-76D9744F-C32E-4197-A654-6064FEDEB19CQ35836872-1DA49283-66B2-4D0B-9ED8-1FD7BE6E6A5BQ35836881-EDCD70A5-C45E-4B17-AA4D-E0C6DE49C7B7Q36037180-557E1933-2D7B-4A78-80AB-F9F9A28387F8Q36476234-594725E1-09CE-480C-99AF-AB1A7F666733Q36664500-91AE37B4-387D-4561-84FE-B09823FAE6B8Q36815262-2C878EEC-EE51-4821-9243-07FCC4BA613EQ37017342-E8D2B5F0-0362-4FA7-ABBB-E289BF4D63E5Q37107439-7F8BABA1-37BE-418E-9436-26594A0679C1Q37237422-FF16BA9B-C8E8-4BD5-875D-DFB148102F27Q37427124-1D766767-9026-418E-9691-8C4A4CD7815DQ37430243-90BAD2ED-0AA4-43E4-99F5-18AFEFF8C77DQ37564440-CD12B3A0-BAA9-458A-8197-85679EE18457Q37564458-5679B45F-258C-40BB-88BF-82272794F5C9Q37625487-8BD02A30-2025-44B3-A160-4FD8D69F1F65Q38124119-55C33329-49D6-47D6-B05F-06169E6996C0Q38905686-E61F472F-BF08-43F9-B61D-95716568C525Q38911003-CD36B37C-B24E-4DAB-A7CD-D5501D37AA15Q39368528-7B00572B-683C-4DEE-83CD-2880C642FD0CQ39507481-EB260EF0-76C6-40BD-B62A-92435BAC552AQ39634615-CBF4391F-7B96-4AE7-9CA2-AE2FCA401F81Q43076940-CFE72D59-0464-403A-9BA4-A2267173D8B2Q45172522-F57FD290-6E55-42FD-85AD-A87F56F2B885Q47096159-77A7A279-63EA-4CB3-B377-07E4ADA56E19Q48076839-C3E57FD1-4A4C-4100-811E-AEC4D2C775A6Q50911306-336B322A-7790-4E39-9F76-5A77DD837E86
P2860
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@en
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@nl
type
label
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@en
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@nl
prefLabel
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@en
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@nl
P2093
P2860
P1433
P1476
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
@en
P2093
Adrian C Newland
Feng-Ting Liu
Ihtesham U Rehman
John G Gribben
Peter B Wyatt
Samir G Agrawal
Zanyar Movasaghi
P2860
P304
P356
10.1182/BLOOD-2008-04-150227
P407
P577
2008-07-16T00:00:00Z